公开(公告)号：US20240059772A1

公开(公告)日：2024-02-22

申请号：US18339837

申请日：2023-06-22

Applicant: BioNTech AG ,  Astellas Pharma Inc. ,  TRON - Translationle Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Korden Walter ,  Meike Wagner ,  Maria Kreuzberg ,  Sabine Hacker ,  Stefan Jacobs

IPC: C07K16/28 ,  G01N33/574 ,  A61K47/68 ,  A61K33/243 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  A61K39/395 ,  A61N5/10 ,  C07K16/30

CPC classification number: C07K16/28 ,  G01N33/57484 ,  A61K47/6851 ,  A61K33/243 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  A61K39/39558 ,  A61N5/10 ,  C07K16/30 ,  G01N33/57492 ,  G01N2800/52 ,  C07K2317/73 ,  A61K2039/505

Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.

公开(公告)号：US20220347308A1

公开(公告)日：2022-11-03

申请号：US17867128

申请日：2022-07-18

Applicant: BIONTECH AG

Inventor： Steve PASCOLO

IPC: A61K47/64 ,  A61P37/04 ,  A61P35/00 ,  A61K39/00 ,  A61K9/51

Abstract: The present invention relates to a method for inducing an immune response manifested by type I interferon production in a synergistic manner comprising the sequential administration of danger signals within a certain timeframe and means for practicing the method. The present invention is particularly useful for immunomodulation, immunotherapy and vaccination.

公开(公告)号：US20210324341A1

公开(公告)日：2021-10-21

申请号：US17241651

申请日：2021-04-27

Applicant: BioNTech AG ,  TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg Universitat Mainz

Inventor： Ugur Sahin ,  Marco Poleganov ,  Tim Beissert

IPC: C12N5/074

Abstract: Methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, include the steps of introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate.

公开(公告)号：US10980875B2

公开(公告)日：2021-04-20

申请号：US15763541

申请日：2016-10-20

Applicant: BIONTECH AG

Inventor： Steve Pascolo

IPC: A61K39/39 ,  A61K39/00

Abstract: The present invention relates to particles comprising RNA, in which the RNA is associated with a cationic polymer or lipid or with both a cationic polymer and lipid, wherein the RNA comprises a cytotoxic nucleotide or cytotoxic nucleotide analog and/or the RNA is covalently attached to a cytotoxin, pharmaceutical compositions containing said particles and pharmaceutical uses of the particles and pharmaceutical compositions. The particles of the present invention are particularly useful as an immunostimulating medicament capable to block proliferation or induce death in dividing cells such as tumor cells.

公开(公告)号：US10858415B2

公开(公告)日：2020-12-08

申请号：US15113981

申请日：2014-01-29

Applicant: BioNTech AG ,  TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg—Universitat Mainz gemeinnutzige GmbH ,  Universitatsmedizin der Johannes Gutenberg—Universitat Mainz ,  JPT Peptide Technologies GmbH

Inventor： Ugur Sahin ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt ,  Laura-Marie Kring (née Plum) ,  Markus Fiedler ,  Ulf Reimer ,  Karsten Schnatbaum

IPC: A61K38/08 ,  A61K38/12 ,  C07K5/00 ,  A61K38/04 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  C07K14/705 ,  C07K7/64 ,  A61K39/00 ,  G01N33/53 ,  G01N33/574

Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

公开(公告)号：US10604568B2

公开(公告)日：2020-03-31

申请号：US14904011

申请日：2014-07-30

Applicant: BioNTech AG ,  Astellas Pharma Inc. ,  TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH

Inventor： Ugur Sahin ,  Ozlem Tureci ,  Korden Walter ,  Meike Wagner ,  Maria Kreuzberg ,  Sabine Hacker ,  Stefan Jacobs

IPC: A61K39/395 ,  A61K47/68 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  C07K16/28 ,  G01N33/574 ,  A61K33/24 ,  A61N5/10 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.

公开(公告)号：US20200031898A1

公开(公告)日：2020-01-30

申请号：US16595440

申请日：2019-10-07

Applicant: BioNTech AG ,  TRON - Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz ,  Universitatsmedizin der Johannes Gutenberg-Universitat Mainz ,  JPT Peptide Technologies GmbH

Inventor： Ugur Sahin ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt ,  Laura-Marie Kring (née Plum) ,  Markus Fiedler ,  Ulf Reimer ,  Karsten Schnatbaum

IPC: C07K14/705 ,  G01N33/53 ,  A61K39/00 ,  G01N33/574

Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.

公开(公告)号：US10457735B2

公开(公告)日：2019-10-29

申请号：US15538419

申请日：2016-01-08

Applicant: BIONTECH AG ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US10370433B2

公开(公告)日：2019-08-06

申请号：US15552215

申请日：2016-03-15

Applicant: BIONTECH AG

Inventor： Ugur Sahin ,  Joycelyn Wüstehube-Lausch ,  Markus Fiedler ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt

IPC: C07K14/81 ,  C07K14/00 ,  C07K5/10

Abstract: The present invention relates to the diagnosis and treatment of cancerous diseases, in particular cancerous diseases expressing Seprase (Fap-alpha; fibroblast activation protein alpha). More particularly, the invention concerns peptides targeting Seprase.

公开(公告)号：US20190192643A1

公开(公告)日：2019-06-27

申请号：US16229841

申请日：2018-12-21

Applicant: BIONTECH AG ,  TRON - Translationale Onkologie an der Universitätsmedizin Mainz Gemeinnützige Gmbh

Inventor： Ugur Sahin ,  Claudia Paret ,  Kirsten Vormbrock ,  Christian Bender ,  Petra Simon ,  Christoph Hartmann ,  Stefanie Hubich ,  Thomas Bukur ,  Thorsten Litzenberger

IPC: A61K39/00 ,  C12Q1/6886 ,  G01N33/574 ,  C07K14/47

CPC classification number: A61K39/0011 ,  A61K2039/507 ,  A61K2039/53 ,  A61K2039/70 ,  C07K14/4748 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57415 ,  G01N33/57484 ,  G01N2333/47

Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.